Retrospective analysis shows imipenem/cilastatin/relebactam effectively treats gram-negative bacterial infections, indicating its role in antibiotic stewardship.
The findings of this study reinforce the value of IMI/REL as an effective and well-tolerated treatment for severe GNB infections in a complex, real-world patient population. These outcomes compare favourably with published data for other new BL/BLI agents, supporting the targeted use of IMI/REL as a crucial component of modern antibiotic stewardship.
No takes yet. Share an insight, caveat, or question.
Petrakis et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: